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Over the last few years, there have been significant challenges in and increased concerns
around anti-microbial resistance (AMR), emerging infectious diseases, and neglected diseases
(NDs). Both AMR and emerging infectious diseases, specifically Ebola, have recently been ele-
vated to the level of public health concerns affecting global security. All these areas have identi-
fiable prevention and management strategies that can and should be scaled up. However, an
additional consistent thread that runs throughout all these global health concerns is the deficit
in innovation of new tools in relation to the identified needs. Therapeutics and vaccines for
Summary Points
• Anti-microbial resistance, emerging infectious diseases, and neglected diseases are all
important public health concerns and priorities with serious market failures, deficits,
and identified needs in biomedical innovation.
• It is important to reconcile, rather than fragment, the needs of these three priority
areas by considering an umbrella framework for specifically financing and coordinat-
ing research and development (R&D) that delivers innovation while securing
patient access.
• A sizeable, sustainably financed global R&D fund and mechanism that promotes coor-
dination, collaboration, and utilization of new and innovative incentives should be set
up to cover all three priority areas.
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Ebola remain experimental and treatments for many neglected diseases remain archaic, while
the current antibiotic pipeline is drying out and will most likely not meet current and future
challenges, even if efforts to rationally use these medicines are stepped up.
The reasons behind these failures of the research and development (R&D) system are
multi-faceted and have been comprehensively described before and widely acknowledged by
the World Health Organization (WHO) and its member states [1]. The consultative expert
working group (CEWG) on R&D Financing and Coordination at WHO reviewed more than
100 proposed ideas and suggested the need for alternative models to fund and incentivize
R&D, supported by a global normative R&D framework that would deliver both innovation
and access, underpinned by certain key principles and a pooled R&D fund [2]. Some aspects
of these models have already been utilized for NDs and are being explored for antibiotics.
The CEWG recommendation for the establishment of an international treaty including man-
datory financial contributions fromWHOmember states has not achieved widespread sup-
port. However, WHO member states have recently indicated support for establishing a fund
with a voluntary financing model that would finance biomedical R&D based on the principles
formulated by the CEWG, namely: de-linkage of the delivery price from R&D costs, the use
of open knowledge innovation, and licensing for access [3,4]. Such principles would allow for
lower cost and more efficient R&D centered on the needs and resources of the people who
need them most. Of note, while large, international, multi-lateral funds exist for global health
delivery (e.g., UNITAID; The Global Fund to Fight AIDS, Tuberculosis and Malaria; the
Gavi Vaccine Alliance), there is no significant large pooled funding mechanism for infectious
disease R&D that works as a multi- or poly-lateral (i.e., with both state and non-state
actors) mechanism.
The idea of a global financing mechanism for innovation has been discussed for global
health priorities in general, NDs, antibiotics, and more recently, Ebola [5–7], but in separate
discussions. All of these are clearly public health priorities, and some may constitute public
health emergencies of international concern (as defined in the International Health Regula-
tions). They provide limited, unpredictable, and therefore unattractive commercial markets.
Many are also priorities for all countries across the low-, middle-, and high-income groupings,
and for all these diseases the medical tools needed to address them should be considered as
global public goods.
Before jumping to create multiple new mechanisms, it would make sense to consider recon-
ciling the needs of all these areas by considering an umbrella framework for specifically funding
and coordinating R&D that not only emphasizes innovation but also secures access. During
the last WHO Executive Board, member states stressed the importance of creating such a
framework, citing the Ebola crisis and AMR to justify its urgent need. From our perspective,
such a framework could provide longer term vision, clear priorities, and increased capacity for
risk-taking, beyond what is feasible given the political constraints of individual national or re-
gional sources of funding. It could address global needs and gaps based on target product pro-
files that can serve a range of contexts, supporting and incentivizing a wide range of existing
and new research entities, public and private, across low-, middle-, and high-income econo-
mies. It could also combine orthodox (e.g., grants) and less traditional incentives (e.g., prizes,
bonds), while promoting the sharing and pooling of knowledge, data, and technologies. The
use of such strategies should be strongly coupled and assist with delivering equitable access to
the fruits of innovation.
However, there are some clear prerequisites required to enable a functional R&D frame-
work. First, we need a specific R&D financing mechanism that, in turn, would need to be
linked closely with one or more entities that have the ability to monitor research flows and
outputs [8]. The mechanism would need to be able to set global priorities according to
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agreed-upon needs and to play a key role in formulating a global strategy, in collaboration
with other actors and funders. Such normative functions mean it would require a strong link
with an inter-governmental agency like the WHO. Further evaluation is required before it
can be considered whether the mechanism needs to sit inside or alongside the United Nations
system, and this may be dependent upon parallel issues such as WHO reform and potential
post-Ebola reforms. The mechanism would need to be essentially publicly financed and
owned and overseen by governments, but private and philanthropic actors and civil society
should be involved as stakeholders. Good governance to ensure oversight and transparency
and an effective, professional, and suitably competent secretariat will be essential. Moreover,
the mechanism must strive to be lean and public-health–oriented, with clear performance
measures, in order to more rapidly deliver needed innovations to patients. The crisis-response
R&D processes elicited by the Ebola outbreak demonstrate that such a mechanism could also
be useful by allowing a more proactive and expeditious approach to address emerging public
health needs.
Both the CEWG and the Lancet Commission on Investing in Health have called for a dou-
bling of global health R&D funding to US$6 billion annually for infections of poverty [2,6]. An
additional investment of around US$4 billion would be needed for AMR and emerging infec-
tions, totaling US$10 billion. Echoing Jim O’Neill’s (Chair of the UK government’s review on
AMR) recent call for a US$2 billion AMR fund, at least US$2–3 billion should be international-
ly pooled [9]. This is necessary to secure sufficient strength of coordination across funders.
However, the fund should not become one large, monopolistic, and monolithic operator. It
should, rather, be in tandem with other large public and private funders, and promote align-
ment, collaboration, and synergy to build a broad investment strategy and portfolio, thereby
hedging for failures, which inevitably are part of the process of biomedical innovation. New
and additional sources of financing would be required, notably from emerging economies, as
well as innovative financing mechanisms.
The events of 2014 have shown that crisis management is more risky and costly, and less
effective, than a prepared health system. This also holds true for the innovation needs, and
demonstrates the need for a preparedness R&D mechanism that can quickly deliver innova-
tive responses to emerging health threats. With a stronger R&D mechanism in place, innova-
tive vaccines and therapeutics could have been ready for testing earlier on in the Ebola
outbreak in West Africa. The need for change must be a call to action to mobilize countries to
take collective action. We believe that such a move that transcends state and corporate inter-
ests would result in a win-win scenario for all—rich and poor populations, and public and pri-
vate sectors alike.
The devastating loss of human life from the Ebola outbreak of 2014 must not be in vain. It
must prompt serious changes to our joint international systems for stimulating innovation and
ensuring access to health technologies for those who need them. These issues must be on the
agenda for the evaluation panels established in the aftermath of Ebola, at World Health Assem-
bly and UN levels. It must also be a key priority at the G7 summit in June 2015 [10]. We call
for one of their recommendations to be the establishment of a global biomedical R&D fund
and mechanism for innovations of public health importance.
Author Contributions
Wrote the first draft of the manuscript: MB JAR. Contributed to the writing of the manuscript:
BP MK PM. Author Contributions: MB CB DH JF NGMK YL PM RM BP LP MT JAR. All au-
thors have read, and confirm that they meet, ICMJE criteria for authorship.
PLOSMedicine | DOI:10.1371/journal.pmed.1001831 May 11, 2015 3 / 4
References
1. Global strategy and plan of action on public health, innovation and intellectual property. Sixty-first World
Health Assembly, 19–24 May 2008, ResolutionWHA61.21. Geneva: World Health Organization; 2008
2. Research and development to meet health needs in developing countries: strengthening global financ-
ing and coordination. Report of the Consultative Expert Working Group on Research and Development:
Financing and Coordination Geneva: World Health Organization; 2012. http://www.who.int/phi/CEWG_
Report_5_April_2012.pdf?ua=1
3. Follow-up of the report on the Consultative Expert Working Group on Research and Development: fi-
nancing and coordination. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_28Add1-en.pdf
4. Røttingen JA, Chamas C, Goyal LC, Harb H, Lagrada L, Mayosi BM. Securing the public good of health
research and development for developing countries. Bull World Health Organ 2012; 90(5):398–400
doi: 10.2471/BLT.12.105460 PMID: 22589577
5. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for eco-
nomic development. Geneva: World Health Organization; 2001 PMID: 12396642
6. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a
world converging within a generation. The Lancet 2013; 382(9908): 1898–955
7. Outterson K. New Business Models for Sustainable Antibiotics. Chatham House, London: Royal Insti-
tute of International Affairs; 2014
8. Røttingen JA, Regmi S, Eide M, Young AJ, Viergever RF, Årdal C et al. Mapping available health R&D
data: what’s there, what’s missing and what role for a Global Observatory. Lancet 2013; 382
(9900):1286–307 doi: 10.1016/S0140-6736(13)61046-6 PMID: 23697824
9. Grogan K. AMR review head O'Neill calls for $2 billion innovation fund. Pharma times. http://www.
pharmatimes.com/Article/15-02-27/AMR_review_head_O_Neill_calls_for_2_billion_innovation_fund.
aspx. Accessed 19 March 2015
10. Yamey G, Campe S, Fewer S. Germany, the G7, and global health. BMJ 2015; Mar 5; 350:h1210. doi:
10.1136/bmj.h1210 PMID: 25744556
PLOSMedicine | DOI:10.1371/journal.pmed.1001831 May 11, 2015 4 / 4
